'EMA Recommends Extending Indication Of Mpox Vaccine To Adolescents' - EMA
Portfolio Pulse from Benzinga Newsdesk
The European Medicines Agency (EMA) has recommended extending the use of the Imvanex vaccine to adolescents aged 12-17. This decision is based on a study showing similar immune responses in adolescents and adults. The vaccine, already authorized for adults in the EU, is crucial for addressing the mpox outbreak in the Democratic Republic of the Congo and other regions. The EMA's recommendation supports WHO's prequalification process, facilitating broader access to the vaccine.
September 19, 2024 | 3:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bavarian Nordic, the company behind the Imvanex vaccine, may see positive impacts from EMA's recommendation to extend the vaccine's use to adolescents. This could lead to increased demand and broader market access, especially in regions affected by mpox.
The EMA's recommendation directly affects Bavarian Nordic as it expands the potential market for their Imvanex vaccine. The extension to adolescents could increase sales and market penetration, especially in areas with urgent mpox needs.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100